Noninvasive and
Convenient Testing

Our Trovera liquid biopsy tests enable physicians to use urine or blood as the sample type, allowing for easy and frequent assessment of mutational status without the need for invasive, more time consuming procedures. Urine is the epitome of a noninvasive, replenishable and convenient ctDNA source.

Ultra-Sensitive
Mutation Detection

Our proprietary Precision Cancer Monitoring® (PCM) technology enables industry-leading sensitivity with detection as low as 0.006%, or ten times greater than other currently available liquid biopsy methods. This sensitivity is the equivalent of detecting one cancer cell per 20,000 non-cancer cells.

Clinically Actionable,
Quantitative Results

We focus our Trovera® tests on mutations that are well documented in treatment guidelines and clinically actionable, helping physicians select from among the most appropriate therapies available. We provide quantitative test results so that physicians can track their patients’ tumor mutation levels and trends before, during and after treatment.

Clinically Actionable,
Quantitative Results

We focus our Trovera® tests on mutations that are well documented in treatment guidelines and clinically actionable, helping physicians select from among the most appropriate therapies available. We provide quantitative test results so that physicians can track their patients’ tumor mutation levels and trends before, during and after treatment.

Order a test

Interested in ordering a sample collection kit?